Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 295

Sort by

Sort Order Select

Journal Articles

Amlsp model for AML survival prediction

Shasha Zhang, Xiangjie Lin, Yiyi Yao, Lijie Wang, Ning Zhang, Jie Jin, Zhaoxiang Wang, Huafeng Wang

Blood (2025) 146 (Supplement 1): 393.

https://doi.org/10.1182/blood-2025-393

Published: 2025

Journal Articles

Benchmark evaluation of large language models in acute myeloid leukemia prognosis

Xiangjie Lin, Di Xu, Nanfang Zhuo, Jingrui Jin, Yujia Wang, Liping Mao, Yinjun Lou, Min Yang, Haitao Meng, Wanzhuo Xie, Jian Huang, Hongyan Tong, Shengli Xue, Yu Zhu, Jie Jin, Jun Wang, Huafeng Wang

Blood (2025) 146 (Supplement 1): 7954.

https://doi.org/10.1182/blood-2025-7954

Published: 2025

Journal Articles

Characteristics and clinical outcomes of ND-AML patients with bcor/bcorl1 mutations

Blood (2025) 146 (Supplement 1): 7005.

https://doi.org/10.1182/blood-2025-7005

Published: 2025

Journal Articles

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations

Blood (2025) 146 (Supplement 1): 3788.

https://doi.org/10.1182/blood-2025-3788

Published: 2025

Journal Articles

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study

Qian Jiang, Weiming Li, Yanli Zhang, Qiang WANG, Suning Chen, Bingcheng LIU, Jie Jin, Zhenfang Liu, Zhuogang Liu, Jianyu Weng, Xin Du, Xielan Zhao, Li Meng, Shujie Yan, xiaomeng Dong, Yihan Wang, Jingrong Cao

Blood (2025) 146 (Supplement 1): 902.

https://doi.org/10.1182/blood-2025-902

Published: 2025

Journal Articles

AP-3 targets the mrgbp/Tip60/MYC axis to exert potent anti T-ALL effects in a Notch1 independent manner

Fenglin Li, Haihui Zhuang, Jie Jin, Ying Lu

Blood (2025) 146 (Supplement 1): 3364.

https://doi.org/10.1182/blood-2025-3364

Published: 2025

Journal Articles

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

Yile Zhou, Liu Ge, Liping Mao, Yinjun Lou, Hao Ai, Qian Wang, Hongyan Tong, Jie Jin, Qingsong Yin, Huafeng Wang

Blood (2025) 146 (Supplement 1): 3336.

https://doi.org/10.1182/blood-2025-3336

Published: 2025

Journal Articles

Evaluation of ims-IP assay for the detection and typing of monoclonal immunoglobulins by mass spectrometry.

Yu Chen, Min Yang, Jie Jin, Haitao Meng

Blood (2025) 146 (Supplement 1): 7869.

https://doi.org/10.1182/blood-2025-7869

Published: 2025

Journal Articles

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Xuewu Zhang, Yunfei Lv, Xiang Zhang, Xingnong Ye, Chunmei Yang, Juying Wei, De Zhou, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2025) 146 (Supplement 1): 3596.

https://doi.org/10.1182/blood-2025-3596

Published: 2025

Journal Articles

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Blood (2025) 146 (Supplement 1): 887.

https://doi.org/10.1182/blood-2025-887

Published: 2025

Journal Articles

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Peipei Ye, Renzhi Pei, Lihong Shou, Jie Jin, Hongyan Tong, Huifang Jiang, Linlong Xu, Jian Shen, Sai Chen, Gongqiang Wu, Dong Chen, Shuangyue Li, Jingcheng Zhang, Huang Li, Fujiang Song, Weiying Feng, Chao Hu, Ying Lu

Blood (2025) 146 (Supplement 1): 5960.

https://doi.org/10.1182/blood-2025-5960

Published: 2025

Journal Articles

Kte-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: 6-month analysis of a phase II multicenter trial

Meng Lv, Hao Jiang, Yuhua Li, Yicheng Zhang, Jie Jin, Hongsheng Zhou, Kailin Xu, Mingfeng Zhao, Xin Du, Kai Hu, Jun Hu, Jinghua Zhao, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2025-1563

Published: 2025

Journal Articles

Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia

Liu Ge, Yile Zhou, Yinjun Lou, Hao Ai, Liping Mao, Qian Wang, Hongfei Wu, Hongyan Tong, Xudong Wei, Jie Jin, Huafeng Wang, Qingsong Yin

Blood (2025) 146 (Supplement 1): 1562.

https://doi.org/10.1182/blood-2025-1562

Published: 2025

Journal Articles

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia

Nanfang Zhuo, Fujie Shi, Xiangjie Lin, Pengfei Chai, Jianai Sun, Nianci Chen, Yi Chen, Jin Lei, Wenxiang Zhao, Jie Jin, Yinghui Zhu, Huafeng Wang

Blood (2025) 146 (Supplement 1): 2355.

https://doi.org/10.1182/blood-2025-2355

Published: 2025

Journal Articles

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Feng Zhu, Yile Zhou, Yi Zhang, Liping Mao, Yinjun Lou, Yu Zhu, Zheng Ge, Zhiyong Zeng, Fengbo Jin, Tingting Liu, Haitao Xu, Yue Yao, Quanyi Lu, Jianxin Guo, Hongyan Tong, Huafeng Wang, Jie Jin

Blood (2025) 146 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2025-1728

Published: 2025

Journal Articles

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

Xiaojing Bao, Tian Zeng, Zhikang Zheng, Bingbing Wen, Rumeng Li, Hongyan Tong, Jie Jin, Jian Huang

Blood (2025) 146 (Supplement 1): 7352.

https://doi.org/10.1182/blood-2025-7352

Published: 2025

Journal Articles

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Qingchi Liu, Lihong Shou, Feng Zhang, Cuicui Wu, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 7351.

https://doi.org/10.1182/blood-2025-7351

Published: 2025

Journal Articles

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Yi Zhang, Hu Zhou, Zhijian Xiao, Minghui Duan, Sujun Gao, Guangsheng He, Hongmei Jing, Junmin Li, Liangming Ma, Huanling Zhu, Chunkang Chang, Xin Du, Mei Hong, Xin Li, Qingchi Liu, Wei WANG, Na Xu, Haiping Yang, Jie Jin

Blood (2025) 146 (Supplement 1): 2029.

https://doi.org/10.1182/blood-2025-2029

Published: 2025

Journal Articles

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Blood (2025) 146 (Supplement 1): 2028.

https://doi.org/10.1182/blood-2025-2028

Published: 2025

Journal Articles

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Blood (2025) 146 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2025-2039

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Amlsp model for AML survival prediction

Benchmark evaluation of large language models in acute myeloid leukemia prognosis

Characteristics and clinical outcomes of ND-AML patients with bcor/bcorl1 mutations

Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study

AP-3 targets the mrgbp/Tip60/MYC axis to exert potent anti T-ALL effects in a Notch1 independent manner

Short-term blinatumomab regimen in newly diagnosed induction and MRD-negative consolidation treatment of B-cell acute lymphoblastic leukemia

Evaluation of ims-IP assay for the detection and typing of monoclonal immunoglobulins by mass spectrometry.

Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study

Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients

Etoposide + cytarabine + pegfilgrastim vs cyclophosphamide + granulocyte colony-stimulating factor for stem-cell mobilization in patients with multiple myeloma: A phase III trial

Kte-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: 6-month analysis of a phase II multicenter trial

Efficacy of short-course versus standard-course blinatumomab in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia

CD84-CD3 bispecific antibody achieves potent anti-leukemic activity with favorable safety profile in Acute Myeloid Leukemia

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Efficacy and safety of gecacitinib in thrombocytopenic myelofibrosis patients

Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only